NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks.
In the past week, the Nordic biotech and healthcare stocks declined another 2.4% and the strong start of the year has almost been erased after poor performance since the end of August. The talk of town last week was Donald Trump’s choice to let the vaccine sceptic RFK Jr. run the U.S. Department of Health and Human Services, which led to massive declines for the Danish vaccine developers. On the other hand, there was good news as well. Gubra presented encouraging phase I obesity data, which led to two major price target upgrades. Curasight announced brain cancer as the first indication for uTREAT, and Saniona gave an update on the long-awaited Tesofensine in Mexico.
Only 7 of the 22 Danish biotech companies had a positive share price development in the past week and just 10 companies have had a positive share price performance year-to-date. Obesity continues to drive the best performances with Gubra, Zealand Pharma, and Pila Pharma having strong YTD performance. Two Danish healthcare stocks with +100% YTD return.
Danish company news
No news in the past week
Ascendis Pharma Reports Third Quarter 2024 Financial Results (Link)
No news in the past week
Third Quarter Report Q3-2024 (Link)
CS MEDICA Expands Presence in Eastern Europe through New Partnership (Link)
Update on the Strategic Rationale Behind CANNORDIC IPO and Aim for Capital Increase (Link)
CS MEDICA Announces Postponement of Financial Reporting Deadlines (Link)
Curasight announces brain cancer as first indication for uTREAT[®]: First patient to be dosed Q2 2025 (Link)
Curasight announces international patent application for uTREAT® to broaden IP protection (Link)
No news the past week
Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1 (Link)
Evaxion receives and appeals delisting determination from Nasdaq, remains committed to Nasdaq listing (Link)
ExpreS2ion and Evaxion announce positive preclinical data for cytomegalovirus (CMV) vaccine program ES2B-I002 (Link)
ExpreS2ion announces financial results for the third quarter of 2024 (Link)
ExpreS2ion announces TO 10 warrant exercise price and start of exercise period (Link)
FluoGuide A/S issue warrants to board member, CMO and CFO (Link)
Genmab got new price targets. Deutsche Bank set their new price target at DKK 2,250 from DKK 2,500 and Carnegie to DKK 2,658 to DKK 2,740.
Gubra announces positive GUBamy Phase 1 SAD data (Link).
Following the positive phase 1 data, the company got new price targets as well at DKK 800 by ABG and DKK 1,200 by Kempen, while the stock is currently trading at DKK 588.
No news the past week
IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights (Link)
Pila Pharma announces progression and co-sponsorship of preclinical research collaboration in cardiovascular disease (Link)
Pila Pharma announces selection of clinical trial site and decision to seek scientific advice for optimized PP-CT03 study design (Link)
Update on Tesofensine Application (Link)
Scandion Oncology – Interim Report Q3 2024 (Link)
SynAct Pharma presents positive clinical data on resomelagon (AP1189) supporting development for the treatment of RA at ACR Convergence (Link)
No news the past week
A board member of Zealand Pharma sold shares worth around 1.2 MDKK (Link)
No news the past week
No news the past week
Share price development – Danish stocks
On average, Danish biotech and healthcare stocks delivered a negative return of 4.5% following Donald Trump’s choice to let vaccine sceptic RFK Jr. run the U.S. Department of Health and Human Services. The table below clearly shows that the vaccine-related stocks were severely hit, while the others had a week of usual performance. For instance, Evaxion Biotech, Y-mAbs Therapeutic, and IO Biotech declined 25-41% without presenting any noticeable negative news. On the flip side, Gubra presented encouraging phase 1 data that led to two major price target increases to DKK 800 and DKK 1,200 respectively. Curasight rose 10% after they announced brain cancer as the first indication for uTREAT, with the first patient to be dosed in Q2 2025. Saniona gave an update on the long-awaited Tesofensine in Mexico. Finally, a board member at Zealand Pharma sold shares worth around 1.2 MDKK.
Gubra continues to be the best-performing stock year-to-date with a return of 388%. Pila Pharma has also generated more than a 100% return, while Zealand Pharma, Y-mAbs Therapeutic, and ViroGates fell below 100% in the past week.
Overview of share price development the past week, year-to-date, and the last twelve month
Nordic Biotech & Healthcare Developments
In the past week, the all-Nordic index Kapital Partner Nordic Healthcare Index (KPHC) declined 2.4% to 61,86. The healthcare index performed strongly from the beginning of October last year until July and August of this year. However, since August the index has declined rapidly alongside the other indexes in the Nordics, and the 1-year return for the KPHC index has almost been erased via the past months of poor performance.
The Nordic healthcare stocks (KPHC) vs. C25, S30, and KPNGX the past year
The top three best-performing stocks in the past week
Eevia Health (43%) offers production protocols and procedures for delivering organic products to international customers. The products are sold to corporate customers and include ingredients for manufacturers of dietary supplements, food, and cosmetics on a global basis. The products include, for example, blueberries, chaga mushrooms, and pine bark
Audientes (38%) is a Danish technology company specializing in the development of hearing aids. Audientes’ hearing aid solution, Ven™ by Audientes, is available in the Indian market, online and through retailers. Audientes’ vision is to develop products that can be used by people suffering from hearing loss who currently do not have access to a solution for their hearing loss.
OssDsign (36%) specializes in the research and development of pharmaceuticals for bone defects. The pharmaceuticals are based on bioceramic material, the composition of which is used to improve the healing process in various cases of patient injuries. The products are resold as implants and are mainly used for the treatment of head injuries.
Resources: Refinitiv Eikon, Cision, Nordnet & company websites
